Second Universal Definition of Heart Failure: Implications for Prevention, Biomarkers, and Global Clinical Practice
Key result
Updated universal definition refines heart failure classification using pre-HF stages, streamlined LVEF phenotypes, and biomarkers.
Why the study?
The 2026 Second Universal Definition of Heart Failure updates recognition, classification, and study of heart failure to improve early detection and etiologic precision.
Key Points
- Summarize the 2026 AHA/ACC/ESC/WHF Second Universal Definition of Heart Failure, focusing on updates to disease classification, biomarker integration, and clinical pathways.
- Synthesized updates from the 2026 AHA/ACC/ESC/WHF Expert Consensus Document across clinical definitions, stages, and phenotypes.
- Evaluated the diagnostic and prognostic role of laboratory biomarkers, including natriuretic peptides, troponins, urine albumin–creatinine ratio, and AI-electrocardiography.
- Reaffirms the stage A to D continuum with expanded criteria for pre-heart failure, standardized cause classifications, and trajectory definitions covering remission, recovery, and worsening disease.
- Simplifies ejection-fraction phenotypes into actionable clinical categories and establishes integrated clinical-laboratory pathways to improve global prevention and management of cardiometabolic disease.
PICO
P
Population
Heart failure
E
Exposure / Comparator
Second Universal Definition of Heart Failure
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The incidence and prevalence of HF have continued to increase over time, and ambiguity in the definition of HF has limited research, earlier diagnosis and prevention strategies. The document introduces a standard classification system for the causes of HF and, rather than defining HF based on strict cutoff values for left ventricular ejection fraction, the updated definition takes into account differences in LVEF by sex, age and ethnicity. The definition emphasizes early identification of people at risk or in the early stages of HF in the hopes of preventing disease progression. Also, the condition is now described as dynamic, with potential for improvement, remission or progression, rather than a fixed diagnosis.”
“The new framework recognizes that heart failure is not a static condition. By focusing on stages of disease, underlying causes and disease trajectories—including improvement, remission and recovery—we can better tailor care and advance prevention efforts.”
“It's very different than heart failure with persistent low ejection fraction, and it's certainly very different from heart failure that started out with more preserved ejection fraction. This is a category of patients who on guideline-directed medical therapy—whatever that has been, either medical therapy or device therapy—have improved ejection fraction, and this is a group of patients we have to continue to monitor clinically both with imaging and also follow-up to make certain that their clinical status remains improved.”
Implication
This commentary highlights crucial recalibrations in the recognition and classification of heart failure, emphasizing early detection, etiologic precision, and the use of biomarkers in clinical practice.
Abstract
The 2026 AHA/ACC/ESC/WHF Expert Consensus Document on the Second Universal Definition of Heart Failure marks an important recalibration of how heart failure is recognized, classified, and studied. The document retains the central insight of the 2021 First Universal Definition—that heart failure is a clinical syndrome supported by structural, functional, biomarker, or congestion evidence—but moves the field toward earlier detection, etiologic precision, and trajectory-based care. This is a comprehensive commentary on the latest updates from the Second Universal Definition of Heart Failure. Its most visible changes include reaffirmation of the stage A to D continuum, stronger emphasis on pre-heart failure, simplification of ejection-fraction phenotypes into clinically actionable groups, a universal classification of causes, and new language for improvement, remission, recovery, worsening heart failure, and decompensated heart failure. For laboratory medicine, the definition is especially relevant because of its emphasis on natriuretic peptides, cardiac troponins, urine albumin–creatinine ratio, and emerging artificial-intelligence electrocardiography. This commentary reviews the main changes in the second definition, highlights implications for heart failure with preserved ejection fraction, obesity, cardiometabolic disease, global implementation, and frameworks for integrated clinical and laboratory pathways.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Tiwari et al. (2026) conducted a review in Heart failure. Second Universal Definition of Heart Failure was evaluated. The Second Universal Definition of Heart Failure provides updated classifications emphasizing pre-heart failure, simplified ejection fraction phenotypes, and integrated biomarker pathways.